What can we learn about dense low density lipoprotein and lipoprotein particles from clinical trials?

Current Opinion in Lipidology

Volumn 7, Issue 6, 1996, Pages 363-368

  Superko, H Robert ^a  

^a Berkeley HeartLab Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANGIOCARDIOGRAPHY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; SHORT SURVEY; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030499355     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199612000-00004     Document Type: Short Survey

References (42)

1. Carlson LA, Rosenhamer G: Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988, 223:405-418.
2. Coronary Drug Project: Clofibrate and niacin in coronary heart disease. JAMA 1975, 231:360-381.
3. Lipid Research Clinics Program: The Lipid Research Clinics coronary prevention trial results: I. Reduction in incidence of coronary heart disease, and II. The relationship of reduction in incidence of coronary heart disease to cholestorel lowering. JAMA 1984, 251:351-374.
4. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, et al.: Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987, 317:1237-1245.
5. Hjermann I, Holme I, Velve BK, Leren P: Effect of diet and smoking intervention on the incidence of coronary heart disease. Lancet 1981, ii:1303-1310.
6. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994, 349:1383-1389.
7. Shepherd J, Cobbe SM, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. NEJM 1995, 333:1301-1307.
8. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. NEJM, 335:1001-1009.
9. Superko HR: New aspects of cardiovascular risk factors including small, dense LDL, homocysteinemia, and Lp(a). Curr Opin Cardiol 1995, 10:347-354.
10. Forrester JS, Merz NB, Bush TL, Cohn JN, Hunninghake DB, Parthasarathy S, Superko HR: Task Force 4. Efficacy of risk factor management. J Am Coll Card 1996, 27:991-1006. This statement addresses the evidence for clinical benefit from management of many CAD risk factors. It is a useful clinical tool and was developed by a panel of experts.
11. Goldbourt U, de Faire U, Berg K: Genetic factors in coronary heart disease. Hingham, MA: Kluwer Academic Publishers; 1994.
12. Genest JJ, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, Silberman SR, Wilson PW, Salem DN, Schaefer EJ: Familial lipoprotein disorders in patients with premature CAD. Circulation 1992, 85:20205-2033.
13. Friedlander Y: Familial clustering of coronary heart disease: a review of its significance and role as a risk factor for the disease. In Genetic factors in coronary heart disease. Edited by Goldbourt U, de Faire U, Berg K. Hingham, MA: Kluwer Academic Publishers; 1994:37-53.
14. Hamsten A, de Faire U: Risk factors for coronary artery disease in families of young men with myocardial infarction. Am J Cardiol 1987, 59:14-19.
15. Krauss RM: Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994, 5:339-349.
16. Slyper AH: Low-density lipoprotein density and atherosclerosis. Unraveling the connection. JAMA 1994, 272:305-308.
17. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990, 82:495-506.
18. Nishina PM, Johnson JP, Naggert JK, Krauss RM: Linkage of atherogenic lipoprotein phenotype to the low-density lipoprotein receptor locus on the short arm of chromosome 19. Proc Natl Acad Sci U S A 1992, 89:708-712.
19. Rotter JI, Bu X, Cantor R, Warden CH, Zia YR, De Meester C, Teryua S, Lockensgard B, Daneshmand S, Brown J et al.: Multilocus genetic determination of LDL particle size in coronary artery disease families [Abstract]. Clin Res 1994, 42:16A.
20. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM: Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988, 260:1917-1921.
21. Krauss RM, Stampfer MJ, Blanche PJ, Holl LG, Ma J, Hennekens CH: Particle diameter and risk of myocardial infarction. Circulation 1994, 90:1-460.
22. Gardner CD, Fortmann SP, Krauss RM: Small low-density lipoprotein particles associated with incidence of coronary artery disease in men and women. Circulation 1996, 93:P14. This manuscript has been accepted for publication in JAMA, September 1996.
23. Phillips NR, Waters D, Havel RJ: Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993, 88:2762-2770.
24. Tornvall P, Bavenholm P, Landou C, Faire U, Hamsten A: Relation of plasma levels and composition of apolipoprotein B containing lipoproteins to angiographically defined coronary artery disease in young patients with myocardial infarction. Circulation 1993, 88:2180-2189.
25. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation 1992, 85:37-45.
26. Krauss RM, Lindgren FT, Williams PT, Kelsey SF, Brensike J, Vranizan K, Detre KM, Levy RI et al.: Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet 1987, ii(8550):62-65.
27. Miller BD, Krauss RM, Cashin-Hemphill L, Blankenhorn DH: Baseline triglyceride levels predict angiographic benefit of colestipol plus niacin therapy in the Cholesterol-Lowering Atherosclerosis Study (CLAS). Circulation 1993, 88:1-363.
28. Hodis HN, Mack WJ: Triglyceride-rich lipoproteins and the progression of coronary artery disease. Curr Opin Lipidol 1995, 6:209-214. This is a good review with emphasis on the findings at the University of Southern California in regard to triglyceride-rich lipoproteins and their interaction with arteriographic change.
29. Watts GF, Mandalia S, Brunt JN, Slavin BM, Coltart DJ, Lewis B: Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St Thomas' Atherosclerosis Regression Study (STARS). Metabolism 1993, 42:1461-1467.
30. Miller BD, Alderman EL, Haskell WL, Fair JM, Krauss RM: Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in Stanford Coronary Risk Intervention Project. Circulation 1996, 94:2146-2153.
31. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoer WV, Mahrer PR, Masteller MJ, Vailas LI et al.: Coronary angiographic changes with lovastatin therapy. Ann Intern Med 1993, 119:969-976.
32. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH: Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994, 90:42-49.
33. Miller BD, Cashin-Hemphill L, Mack WJ, Hodis HN, Krauss RM: Predominance of mid-density low density lipoproteins predicts angiographic benefit of lovastatin in the Monitored Atherosclerosis Regression Study. Circulation 1994, 90:1-460.
34. Dreon DM, Fernstrom H, Miller B, Krauss RM: Low density lipoprotein subclass patterns and lipoprotein response to a reduced-fat diet in men. FASEB J 1994, 8:121-126.
35. Yuan J, Tsai MY, Hunninghake DB: Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis 1994, 110:1-11.
36. Superko HR, Krauss RM: Reduction of small, dense LDL by gemfibrozil in LDL subclass pattern B. Circulation 1995, 92:1-250.
37. Dachet C, Cavallero E, Martin C, Girardot G, Jacotot B: Effect of gemfibrozil on the concentration and composition of very low density and low density lipoprotein subfractions in hypertriglyceridemic patients. Atherosclerosis 1995, 113:1-9.
38. Franceschini G, Lovati MR, Manzoni C, Michelagnoli S, Pazzucconi F, Gianfranceschi G, Vecchio G, Sirtori CR: Effect of gemfibrozil treatment in hypercholesterolemia on low density lipoprotein (LDL) subclass distribution and LDL-cell interaction. Atherosclerosis 1995, 114:61-71.
39. Foger B, Trobinger G, Ritsch A, Lechleitner M, Hopferwieser T, Menzel HJ, Utermann G, Pfeiffer KP, Patsch JR: Treatment of primary mixed hyperlipidemia with etophylline clofibrate: effects on lipoprotein-modifying enzymes, postprandial lipoprotein metabolism, and lipoprotein distribution and composition. Atherosclerosis 1995, 117:253-261.
40. Superko HR and KOS investigators: Effect of nicotinic acid on LDL subclass patterns. Circulation 1994, 90:I-504.
41. Franceschini G, Cassinotti M, Vecchio G, Gianfranceschi G, Pazzucconi F, Murakami T, Sirtori M, D'Acquarica AL, Sirtori CR: Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. Arterioscler Thromb 1994, 14:1569-1575.
42. Homma Y, Ozawa H, Kobayashi T, Yamaguchi H, Sakane H, Nakamura H: Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyperlipoproteinemia. Atherosclerosis 1995, 114:223-234.